Last reviewed · How we verify
NCT03952923
CD19-CAR-T in B-cell Malignancies Patients
Phase 1 trial testing CD19-CAR-T cells in B-cell Malignancy in 11 participants. Completed in 31 March 2021.
1 January 2021
Quick facts
| Lead sponsor | Hebei Yanda Ludaopei Hospital |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 11 |
| Start date | 1 August 2019 |
| Primary completion | 1 January 2021 |
| Estimated completion | 31 March 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- CD19-CAR-T cells
Conditions studied
- B-cell Malignancy — all drugs for B-cell Malignancy →
Sponsor
Hebei Yanda Ludaopei Hospital
Who can join
Adults 1 to 70, any sex, with B-cell Malignancy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single center, single arm, open-lable phase I study to determine the safety and efficacy of CD19-CAR-T cells in patients with refractory and relapsed B-cell malignancies.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
CAR-modified immune cells as a rapidly evolving approach in the context of cancer immunotherapies.
Faeq MH, Al-Haideri M, Mohammad TAM, Gharebakhshi F, et al · · 2023 · cited 7× · PMID 37083979 · DOI 10.1007/s12032-023-02019-4
Verify or expand the search:
- PubMed search for NCT03952923
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for B-cell Malignancy
Currently open trials in the same condition.
- NCT06634589 — A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relap · Phase 1, PHASE2 · recruiting
- NCT05294731 — Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Deg · Phase 1, PHASE2 · recruiting
Other Hebei Yanda Ludaopei Hospital trials
Trials by the same sponsor.
- NCT05590091 — Study on Intelligent Nutrition Support Therapy for Hematopoietic Stem Cell Transplantation Recipients · NA · unknown
- NCT05518357 — LILRB4 STAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia · Phase 1 · completed
- NCT04508842 — CD19/CD22-Dual-STAR-T for Patients With B Cell Acute Leukemia(B-ALL) · Phase 1 · terminated
- NCT04260945 — CD19/CD20 Dual-CAR-T in B-cell Leukemia Patients · Phase 1 · completed
- NCT04260932 — CD19/CD20 Dual-CAR-T in B-cell Lymphoma Patients · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03952923 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hebei Yanda Ludaopei Hospital
- Last refreshed: 1 February 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03952923.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing